CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Nonablative Fractional Diode Laserdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04203745
NCT04203745N/ACompleted

Clinical Evaluation of a Nonablative Fractional 1940 nm Diode Laser for Skin Resurfacing and Treatment of Pigmented Lesions

Candela Corporation·interventional·Posted Dec 18, 2019·Updated Aug 1, 2023

In Brief

A clinical study evaluating Nonablative Fractional Diode Laser for Skin Texture and Pigmented Lesions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study is intended to evaluate the efficacy and safety of a new diode fractional laser for skin resurfacing and treatment of pigmented lesions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 18, 2019
Enrollment StartSep 18, 2019
Primary CompletionApr 30, 2021
Study CompletionAug 5, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.5 years ago

Interventions

Nonablative Fractional Diode Laserdevice

The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.